SK Biopharmaceuticals (326030) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, SK Biopharmaceuticals (326030) reported revenue of 706.7 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025706.7 billion KRW203.9 billion KRW253.3 billion KRW[source]
2024547.6 billion KRW96.3 billion KRW227.0 billion KRW[source]
2023354.9 billion KRW-37.5 billion KRW-35.4 billion KRW[source]
2022246.2 billion KRW-131.1 billion KRW-139.4 billion KRW[source]
2021418.6 billion KRW95.0 billion KRW64.8 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025955.5 billion KRW156.3 billion KRW799.2 billion KRW[source]
2024842.1 billion KRW289.0 billion KRW553.1 billion KRW[source]
2023570.7 billion KRW268.8 billion KRW301.9 billion KRW[source]
2022610.9 billion KRW288.5 billion KRW322.4 billion KRW[source]
2021635.6 billion KRW167.4 billion KRW468.2 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice